



OPEN ACCESS

RESEARCH PAPER

Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B

Toshiaki Takahashi,¹ Masashi Aoki,² Naoki Suzuki,² Maki Tateyama,² Chikako Yaginuma,³ Hitomi Sato,³ Miho Hayasaka,^{3,4} Hitomi Sugawara,³ Mariko Ito,^{3,5} Emi Abe-Kondo,^{3,6} Naoko Shimakura,² Tohru Ibi,^{7,8} Satoshi Kuru,⁹ Tadashi Wakayama,^{9,10} Gen Sobue,¹¹ Naoki Fujii,¹² Toshio Saito,¹³ Tsuyoshi Matsumura,¹³ Itaru Funakawa,¹⁴ Eiichiro Mukai,¹⁵ Toru Kawanami,¹⁶ Mitsuya Morita,¹⁷ Mineo Yamazaki,¹⁸ Takashi Hasegawa,^{19,20} Jun Shimizu,²¹ Shoji Tsuji,²¹ Shigeki Kuzuhara,^{22,23} Hiroyasu Tanaka,¹ Masaru Yoshioka,^{1,3} Hidehiko Konno,¹ Hiroshi Onodera,¹ Yasuto Itoyama^{2,24}

► Additional supplementary files are published online only. To view these files please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2011-301339>).

For numbered affiliations see end of article

Correspondence to

Dr M Aoki, Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryō-machi, Sendai 980-8574, Japan; aokim@med.tohoku.ac.jp

Received 2 September 2011

Revised 18 April 2012

Accepted 13 May 2012

Published Online First

15 December 2012

ABSTRACT

Objective and methods Dysferlin encoded by *DYSF* deficiency leads to two main phenotypes, limb girdle muscular dystrophy (LGMD) 2B and Miyoshi myopathy. To reveal in detail the mutational and clinical features of LGMD2B in Japan, we observed 40 Japanese patients in 36 families with LGMD2B in whom dysferlin mutations were confirmed.

Results and conclusions Three mutations (c.1566C>G, c.2997G>T and c.4497delT) were relatively more prevalent. The c.2997G>T mutation was associated with late onset, proximal dominant forms of dysferlinopathy, a high probability that muscle weakness started in an upper limb and lower serum creatine kinase (CK) levels. The clinical features of LGMD2B are as follows: (1) onset in the late teens or early adulthood, except patients homozygous for the c.2997G>T mutation; (2) lower limb weakness at onset; (3) distal change of lower limbs on muscle CT at an early stage; (4) impairment of lumbar erector spinal muscles on muscle CT at an early stage; (5) predominant involvement of proximal upper limbs; (6) preservation of function of the hands at late stage; (7) preservation of strength in neck muscles at late stage; (8) lack of facial weakness or dysphagia; (9) avoidance of scoliosis; (10) hyper-Ckaemia; (11) preservation of cardiac function; and (12) a tendency for respiratory function to decline with disease duration. It is important that the late onset phenotype is found with prevalent mutations.

INTRODUCTION

Dysferlinopathies are autosomal recessive muscular dystrophies caused by mutations in the dysferlin gene (*DYSF*; MIM# 603009). Dysferlin deficiency leads to two main phenotypes: limb girdle muscular dystrophy (LGMD) 2B and Miyoshi myopathy (MM).^{1,2} Dysferlin is located on the plasma membrane of skeletal muscle and is deficient in patients with MM and LGMD2B.^{3,4} However, atypical immunostaining in muscle from patients with dysferlin mutations occurs,^{5,6} and dysferlin expression is not normal in sarcoglycanopathy, dystrophinopathy,⁷ caveolinopathy^{8,9} or calpainopathy⁶ muscles. Therefore, the final diagnosis of dysferlinopathy

requires identification of mutations in the dysferlin gene. We first reported dysferlin mutations in Japanese patients with MM¹⁰ and in a patient from a non-European ethnic group with distal anterior compartment myopathy (DACM),¹¹ a relatively new phenotype of dysferlinopathy.¹² Furthermore, we revealed that, in MM, four mutations (c.1566C>G, c.2997G>T, c.3373delG and c.4497delT) were relatively more prevalent in the Japanese population and the c.2997G>T mutation was associated with late onset.¹³ Although mutation analysis of the dysferlin gene is a time consuming task because of the large size of the gene,¹⁴ large series of patients with dysferlin gene mutations have been studied.^{6,15–24} However, few detailed analyses of the clinical features of LGMD2B, especially in relation to various types of mutations, have been reported. Here we report the clinical features of a series of 40 patients in 36 families with LGMD2B in whom dysferlin mutations were confirmed, and cardiac and respiratory functions were involved. In particular, we took into account the duration that had elapsed since onset when the clinical data were examined.

MATERIALS AND METHODS

We retrospectively observed 40 Japanese patients in 36 families with LGMD2B in whom dysferlin mutations were confirmed. LGMD was defined as symptomatic myopathy excluding MM and DACM at the first visit to a neurologist. Mutational analysis was performed by single strand conformation polymorphism analysis and sequencing on genomic DNA using our previously reported method,^{13,14,25} with minor modifications (Ref Seq NM_003494.2), and with informed consent and approval of our local ethics committee. We retrospectively reassessed the history of onset and progression of the disease. The clinical examination included manual muscle testing using the Medical Research Council (MRC) Scale and assignment of scales for the proximal limb muscles, as proposed by Brooke *et al.*²⁶ Clinical examination was carried out by neurologists from the study groups for muscular dystrophy in Japan.



Open Access
Scan to access more
free content

Most patients had undergone muscle CT scans at some stage of the disease. Serum creatine kinase (CK) activity was measured. Cardiac and respiratory functions were evaluated. We selected the first and last manual muscle testing data and the last data on the scales for the proximal limb muscles, CK activity, cardiac function and respiratory function. We used all muscle CT scans. Patients were divided into three groups according to whether they had the homozygous c.2997G>T (p.Trp999Cys) mutation, the heterozygous c.2997G>T (p.Trp999Cys) mutation or other mutations. Difference in age at onset among the groups was evaluated by the Kruskal–Wallis test. Multiple comparison of age at onset between each group was assessed by Scheffé's F test. Difference in the first symptom among the groups was evaluated by the χ^2 for independence test. Kaplan–Meier curves with log rank test were used to examine survival at each milestone of progression in the groups. Pearson's correlation coefficient test was used to identify significant associations in ejection fraction (EF) (n=21), atrial natriuretic peptide (n=9), brain natriuretic peptide (n=7), per cent vital capacity (%VC) (n=23), carbon dioxide partial pressure (pCO₂) (n=16) and oxygen partial pressure (pO₂) (n=16) with disease duration. Because supine and standing position chest x-rays were mingled, Pearson's correlation coefficient test was not used for the cardiothoracic ratio (n=22).

RESULTS

Mutations

We identified 17 different mutations in 36 families (table 1). Two mutations (c.2974T>C (p.Trp992Arg) and c.2997G>T (p.Trp999Cys)) were missense mutations and four mutations (c.342+1G>A, c.937+1G>A, c.2643+1G>A and c.4794+1G>A) were splice site mutations. The others were nonsense mutations. The c.2997G>T (p.Trp999Cys) mutation was present in 26 alleles (36.1%). The c.1566C>G (p.Tyr522X) mutation and the c.4497delT mutation were both present in eight alleles (11.1%). We identified the c.3373delG mutation that has high frequency in Japanese patients with MM¹³ in only one allele.

Clinical course

Mean age at onset of all patients was 26.6±9.9 years (range 14–58); the group homozygous for the c.2997G>T (p.Trp999Cys) mutation, 37.9±10.2 years (19–58); the group heterozygous for the c.2997G>T (p.Trp999Cys) mutation, 26.8±7.6 years (14–35); and the group without the c.2997G>T (p.Trp999Cys) mutation, 21.8±5.8 years (14–41). The difference between the group homozygous for the c.2997G>T (p.Trp999Cys) mutation and the group heterozygous for the c.2997G>T (p.Trp999Cys) mutation was significant (p<0.05). The difference between the group homozygous for the c.2997G>T (p.Trp999Cys) mutation and the group without the c.2997G>T (p.Trp999Cys) mutation was significant (p<0.01) (figure 1). The first symptom in most patients was lower limb weakness. Walking on tiptoe was the first sign in one patient. In three patients with the homozygous c.2997G>T (p.Trp999Cys) mutation, the first symptom was upper limb weakness. In two patients, one of them carrying the homozygous c.2997G>T (p.Trp999Cys) mutation, upper limb weakness was concomitant with lower limb weakness. There was a significant difference (p<0.01) in the probability that the first symptom was upper limb weakness among these three groups. The first symptom in one patient was left brachial pain and in another patient it was limitation of the elbow, hip, knee and spine.²⁷ In the early stage of the clinical

course, hypertrophy of the calves was noticed in three patients. Winged scapula, rigid spine²⁷ and hollow foot were observed in one patient each. Lordosis was observed in two patients. Weakness of the face, dysphagia, scoliosis and kyphosis were not found. Choreic movements and pollakisuria were found in one patient.²⁸ Mean duration at difficulty in running was 1.3 years from disease onset (range 0–10), 3.1 years (0–14) for difficulty in climbing stairs, 5.5 years (0–16) for stumbling, 6.0 years (0–10) for difficulty in standing on tiptoe, 6.7 years (0–15) for rising from the floor, 8.7 years (0–25) for noticing weakness in a proximal upper limb, 12.5 years (3–23) for walking with a cane, 20.4 years (9–35) for noticing weakness in a distal upper limb, 21.6 years (13–29) for using a wheelchair and 31.0 years (16–45) for using an electric wheelchair. There was a significant difference (p<0.05) in the survival ratio only at the stage of difficulty in standing on tiptoe among these three groups (figure 2). There were no significant differences in survival at the stage of the other symptoms between these three groups. According to the scales for the proximal limb muscles, only two patients each reached the severest stage of arms and shoulders (cannot raise hands to mouth and have no useful function) and hips and legs (confined to bed).

Manual muscle testing

In the first decade of the disease, the muscles of the lower limbs were predominantly involved. In the upper limbs, the deltoid muscle was predominantly involved. In the second decade of the disease, the biceps and triceps brachii muscles became weak. Later on, the flexor and extensor of the hand became weak. Muscle weakness progressed and, in the fifth decade of the disease, the muscles of the lower limbs were very weak (1 on the MRC Scale). In the patient with 52 years of disease duration, although the muscles of the upper and the lower limbs were 0 on the MRC scale, the flexor and extensor of the neck were relatively preserved (2 on the MRC Scale).

Muscle CT scans

The CT scans revealed low density changes in the gastrocnemius, especially in the medial heads, soleus, hamstrings and the erector spinal group, which was mainly affected in the lateral parts in the early disease stage. Low density abnormalities in the quadriceps femoris and the adductor magnus muscles were observed at close to 10 years after disease onset. The tibialis anterior, the peroneal group, the gluteal group, the quadratus lumborum and the deltoid muscles were involved at 10 years after onset. The gracilis and sartorius muscles were preserved and had hypertrophied during the second decade of disease duration. Approximately 20 years after disease onset, low density changes in the dorsal muscles occurred in the neck region, particularly in the transversospinal group, except for the semispinalis capitis muscle. All muscles were replaced by low density tissue or were atrophied at 30 years after disease onset. The gluteal group, the psoas major muscle, the lateral abdominal group and the levator scapulae muscle were preserved in the late stage. There were exceptional cases. In one patient, low density changes in the dorsal muscles in the neck region occurred at an early stage. In another patient, the quadriceps femoris muscles were more severely damaged than the hamstrings at 14 years of disease duration.

Serum CK levels

Although serum CK levels were very high, there was a tendency for levels to decrease with disease duration (figure 3). There was a trend in the distribution of the levels by

Table 1 Summary of dysferlin gene mutations of patients in this study

Patient	Sex	Age (years)	Disease duration (years)	Exon	Nucleotide change	Protein change	State
Dys48-1	M	54	23	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys58-1	F	51	8	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys64-1	M	58	19	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys93-1	F	57	17	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys99-1	F	55	11	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys106-1	F	22	3	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys113-1	M	57	17	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys123-1	F	59	25	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys133-1	M	66	8	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys170-1	F	38	7	28	c.2997G>T	p.Trp999Cys	Homozygous
Dys13-1	M	43	29	28 34	c.2997G>T c.3771G>A	p.Trp999Cys p.Trp1257X	Compound heterozygous
Dys55-1	F	47	22	28 37	c.2997G>T c.3959_3960insA	p.Trp999Cys p.Met1320IlefsX26	Compound heterozygous
Dys114-1	M	50	15	Intron 25 28	c.2643+1G>A c.2997G>T	Splice site p.Trp999Cys	Compound heterozygous
Dys120-1	M	55	25	18 28	c.1566C>G c.2997G>T	p.Tyr522X p.Trp999Cys	Compound heterozygous
Dys124-1	F	36	12	18 28	c.1566C>G c.2997G>T	p.Tyr522X p.Trp999Cys	Compound heterozygous
Dys127-1	F	56	23	18 28	c.1566C>G c.2997G>T	p.Tyr522X p.Trp999Cys	Compound heterozygous
4	M	75	49	Intron 25 41	c.2643+1G>A c.4497delT	Splice site p.Phe1499LeufsX4	Compound heterozygous
5	M	Died at 59	Died at 42	21	c.1958delG	p.Gly653ValfsX3	Homozygous
15	F	50	34	37	c.3959_3960insA	p.Met1320IlefsX26	Homozygous
39	F	74	52	Intron 25	c.2643+1G>A	Splice site	Homozygous
44	M	41	14	29 41	c.3112C>T c.4497delT	p.Arg1038X p.Phe1499LeufsX4	Compound heterozygous
47	M	55	37	37	c.3959_3960insA	p.Met1320IlefsX26	Homozygous
Dys37-1	M	60	40	Intron 10	c.937+1G>A	Splice site	Homozygous
Dys37-2	F	51	24	Sister of Dys37-1			
Dys43-1	F	36	19	18	c.1566C>G	p.Tyr522X	Homozygous
Dys43-2	F	35	21	Sister of Dys43-1			
Dys46-1	F	67	48	41	c.4497delT	p.Phe1499LeufsX4	Homozygous
Dys50-2	M	70	29	41	c.4497delT	p.Phe1499LeufsX4	Homozygous
Dys59-1	F	49	27	28	c.2974T>C	p.Trp992Arg	Homozygous
Dys61-1	F	43	21	41	c.4497delT	p.Phe1499LeufsX4	Homozygous
Dys78-1	F	54	30	Intron 10	c.937+1G>A	Splice site	Homozygous
Dys84-1	F	64	45	14	c.1321C>T	p.Gln441X	Homozygous
Dys84-2	M	52	32	Brother of Dys84-1			
Dys89-1	F	68	40	18 28	c.1566C>G c.2974T>C	p.Tyr522X p.Trp992Arg	Compound heterozygous
Dys117-1	M	32	9	18	c.1566C>G	p.Tyr522X	Homozygous
Dys117-2	M	30	16	Brother of Dys117-1			
Dys126-1	M	23	2	Intron 4 54	c.342+1G>A c.6135G>A	Splice site p.Trp2045X	Compound heterozygous
Dys145-1	F	27	10	6	c.610C>T	p.Arg204X	Homozygous
Dys146-1	F	58	34	31 Intron 43	c.3373delG c.4794+1G>A	p.Glu1125LysfsX9 splice site	Compound heterozygous
Dys163-1	M	36	11	6	c.493delC	p.Leu165SerfsX48	Homozygous

c.2997G>T (p.Trp999Cys) mutation. Levels in the group homozygous for the c.2997G>T (p.Trp999Cys) mutation were lower than those of the other two groups.

Cardiac function

Although supine and standing position chest x-rays were mingled, in half of the patients the cardiothoracic ratio was

>50%. No significant correlation was observed between EF and disease duration. Except for two patients, levels of EF were >50%. In all the patients, concentrations of atrial natriuretic peptide were within the normal range. Except for one patient, concentrations of brain natriuretic peptide were within the normal range. No significant correlation was observed between these peptides and disease duration. Although 19 patients




Figure 1 Histogram by age at onset. (A) Patients homozygous for the c.2997G>T mutation. (B) Patients heterozygous for the c.2997G>T mutation. (C) Patients without the c.2997G>T mutation.

exhibited normal findings on ECG, abnormalities were found in nine patients. The ECG showed premature ventricular contraction in one patient, one degree atrioventricular block in two patients, incomplete right bundle branch block in two patients, left axis deviation in two patients, left atrial hypertrophy in one patient, right ventricular hypertrophy in three patients, left ventricular hypertrophy in three patients, ST change in two patients and negative T in one patient.




Figure 2 Standing on tiptoe—possible survival curve. Survival curve of patients homozygous for the c.2997G>T mutation (line with squares), those heterozygous for the c.2997G>T mutation (line with triangles) and those without the c.2997G>T mutations (line with diamonds).




Figure 3 Serum creatine kinase (CK) levels during the disease course. Levels of serum CK in patients homozygous for the c.2997G>T mutation (squares), heterozygous for the c.2997G>T mutation (triangles) and those without the c.2997G>T mutations (diamonds).

Respiratory function

A statistically significant ($p < 0.01$) correlation ($r = -0.545$) was observed between %VC and disease duration (figure 4). In 48% of patients, %VC was $< 80\%$. Although no significant correlation was observed between pCO_2 and disease duration, in 44% of patients, levels of pCO_2 were > 45 mm Hg. In most patients, levels of pO_2 were > 70 mm Hg. No significant correlation was observed between pO_2 and disease duration. Four patients had




Figure 4 Respiratory function. (A) Per cent vital capacity (%VC) according to disease duration. The line is the regression line of %VC and disease duration. (B) Carbon dioxide partial pressure (pCO_2) according to disease duration. (C) Oxygen partial pressure (pO_2) according to disease duration. The triangles indicate levels in patients who had used non-invasive positive pressure ventilation. The cross (+) indicates the level in a patient who died after 42 years of disease duration of respiratory failure.

used non-invasive positive pressure ventilation (NIPPV). One patient who used NIPPV died after 42 years of disease duration from respiratory failure.

DISCUSSION

Three mutations (c.2997G>T (p.Trp999Cys), c.1566C>G (p.Tyr522X) and c.4497delT) were relatively more prevalent in the present Japanese patients with LGMD2B. Also, in Japanese patients with MM, these three mutations were relatively more prevalent in our previous study.¹³ We identified the c.3373delG mutation that occurred with high frequency in Japanese patients with MM, as well as these three mutations,¹³ in only one allele in Japanese patients with LGMD2B.

In MM, patients with the c.2997G>T (p.Trp999Cys) mutation had a significantly late onset.¹³ Tagawa *et al*⁶ reported that age of onset in patients homozygous for the c.2997G>T (p.Trp999Cys) mutation was later than the third decade of life. In this study, especially in patients homozygous for the c.2997G>T (p.Trp999Cys) mutation, onset was significantly late. Only 10% of patients homozygous for the c.2997G>T (p.Trp999Cys) mutation developed muscle symptoms by 30 years. In contrast, 90% of patients without this mutation developed muscle symptoms by the same age. However, it is difficult to explain why the c.2997G>T (p.Trp999Cys) mutation is related to late onset forms. In an immunohistochemical analysis by Tagawa *et al*,⁶ although one patient with the homozygous c.2997G>T mutation (p.Trp999Cys) showed an 'abnormal' pattern, cytoplasmic accumulation of immunopositive material with deficiency of membrane staining or positive/negative mosaic membrane staining, three patients with the same mutation showed a negative pattern. Guglieri *et al*²¹ reported that patients carrying two truncating mutations showed the first muscular symptoms earlier in life than subjects harbouring double missense substitutions. Indeed, the c.2997G>T mutation is theoretically deduced to be a missense mutation (p.Trp999Cys). Meanwhile, in this study, there were only two patients carrying missense mutations other than the c.2997G>T (p.Trp999Cys) mutation. Thus it is difficult to discuss statistically whether an association between the c.2997G>T (p.Trp999Cys) mutation and late onset forms is due to a missense mutation or other inherent characteristics. Nonetheless, it is important that the late onset phenotype is found with prevalent mutations.

Although patients homozygous for the c.2997G>T (p.Trp999Cys) mutation had late onset, no difference in progression was observed in those harbouring the c.2997G>T (p.Trp999Cys) mutation, except for difficulty in standing on tiptoe. This suggests that the c.2997G>T (p.Trp999Cys) mutation is related to late onset but not to the slow progression of the disease. Furthermore, the c.2997G>T (p.Trp999Cys) mutation may be relevant to the proximal dominant impairment in dysferlinopathy, diagnosed as the limb girdle type. Interestingly, there was only one patient homozygous for the c.2997G>T (p.Trp999Cys) mutation in 27 families with MM.¹³ Moreover, patients homozygous for the c.2997G>T (p.Trp999Cys) mutation had a high probability that the muscle weakness started in the upper limbs. In addition, serum CK levels in patients homozygous for the c.2997G>T (p.Trp999Cys) mutation were lower than those in the other two groups.

We investigated the clinical features of 40 patients in 36 families with LGMD2B in whom dysferlin mutations were confirmed. Disease duration was long (26.6±9.9 years) in this study. The clinical features of LGMD2B in this study were as

follows: (1) onset in the late teens or early adulthood except in patients homozygous for the c.2997G>T (p.Trp999Cys) mutation; (2) lower limb weakness at onset in most patients; (3) distal change of lower limbs on muscle CT in the early stage; (4) impairment of lumbar erector spinal muscles on muscle CT in the early stage; (5) predominant involvement of the proximal upper limbs; (6) preservation of function of the hands in late stage; (7) preservation of strength in the neck muscles in late stage; (8) lack of facial weakness or dysphagia; (9) avoidance of scoliosis; (10) hyper-Ckaemia; (11) preservation of cardiac function; and (12) tendency for respiratory function to decline with disease duration and occasional necessity for ventilatory assistance.

Age at onset was similar to that reported for various types of mutations.^{18 19 21} However, patients with disease onset at 73 years^{24 29} or congenital onset³⁰ have been reported. Clinicians may not have taken into account analyses of the dysferlin gene for such patients.

Nishida *et al* proposed the name 'distal limb girdle type muscular dystrophy' for patients with MM that develop proximal muscle involvement relatively early.^{31 32} Nguyen *et al*¹⁷ classified patients for whom it was not possible to distinguish between a distal phenotype of MM and a limb girdle phenotype, even when examined at onset, as a distinct 'proximodistal' phenotype group. Although patients with the typical features of MM^{13 35} or asymptomatic hyper-CKaemia were excluded from the present study, variable patterns of weakness in the lower limbs were observed, as in previous studies.^{17 19 20 22 24} However, the predominant muscle weakness was in proximal sites of the upper limbs in the present study.

The results of muscle CT scan in this study were similar to those of detailed imaging studies in LGMD2B at a relatively early stage.^{23 34 35} In this study, we had only one case in whom a low density change in the dorsal muscle in the neck region occurred in the early stage. In contrast, two patients showed fatty muscle degeneration of the cervical elector spinae muscles after 9 or 10 years of disease duration, in a study performed using 3.0 T MRI.³⁵ Another exceptional finding was a case in which the quadriceps femoris muscles were more severely damaged than the hamstrings, which was reported in two of five patients.³⁴

In the present study, only two patients showed levels of EF that were <50% and the patient who showed the lowest EF (32.7%) had no symptoms or signs of cardiomyopathy.³⁶ Guglieri *et al*²¹ reported cardiac rhythm changes in three patients and left ventricular hypertrophy in four patients from a total of 22 LGMD2B patients. Wenzel *et al*³⁷ reported ECG abnormalities (repolarisation abnormalities or left ventricular hypertrophy) in four patients and pathological echocardiographic parameters in five of seven LGMD2B patients. Furthermore, two patients had symptoms and signs of dilated cardiomyopathy. Choi *et al*³⁸ reported left ventricular hypertrophy on ECG in two patients, no cardiac signs in one patient and mildly decreased EF (45%) in one patient among five MM patients. Therefore, we think that in most patients with LGMD2B, in spite of the existence of laboratorial abnormalities, cardiac function was clinically preserved.

Mahjneh *et al*¹⁶ reported that patients with LGMD2B with disease durations of up to 7 years might show slight restrictive lung disease. Cagliani *et al*³⁹ reported that respiratory tests showed mild obstructive signs at the small airways in a 20-year-old man with LGMD2B. Illa *et al*¹² reported that pulmonary function tests revealed a mild reduction in VC in two

patients with DACM. In this study, many patients showed pathological levels of respiratory parameters and levels of %VC decreased with disease duration. Furthermore, some patients needed NIPPV and one patient died of respiratory failure. The change in muscles related to respiratory function worsens with disease duration. Therefore, it is important to pay attention to respiratory function in patients with dysferlinopathy.

Author affiliations

- ¹Department of Neurology and Division of Clinical Research, National Hospital Organization Nishitaga National Hospital, Sendai, Japan
- ²Department of Neurology, Tohoku University School of Medicine, Sendai, Japan
- ³Department of Clinical Laboratory and Division of Clinical Research, National Hospital Organization Nishitaga National Hospital, Sendai, Japan
- ⁴Department of Clinical Laboratory, National Hospital Organization Fukushima National Hospital, Fukushima, Japan
- ⁵Department of Clinical Laboratory, National Hospital Organization Sendai Medical Centre, Sendai, Japan
- ⁶Department of Clinical Laboratory, Sagami Hospital of Rehabilitation, Sagami, Japan
- ⁷Department of Neurology, Aichi Medical University, Aichi, Japan
- ⁸Division of Pathophysiology and Therapeutics, College of Nursing, Aichi Medical University, Aichi, Japan
- ⁹Department of Neurology, National Hospital Organization Suzuka National Hospital, Mie, Japan
- ¹⁰Dr Wakayama's office, Nagoya, Japan
- ¹¹Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- ¹²Department of Neurology, National Hospital Organization Omura National Hospital, Fukuoka, Japan
- ¹³Department of Neurology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
- ¹⁴Department of Neurology, National Hospital Organization Hyogo-Cyuo National Hospital, Hyogo, Japan
- ¹⁵Department of Neurology, National Hospital Organization Nagoya Medical Centre, Nagoya, Japan
- ¹⁶Division of Neurology, Third Department of Internal Medicine, Yamagata University Faculty of Medicine, Yamagata, Japan
- ¹⁷Division of Neurology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan
- ¹⁸Division of Neurology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
- ¹⁹Division of Neurology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
- ²⁰Department of Internal Medicine, Asao General Hospital of Rehabilitation, Kawasaki, Japan
- ²¹Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
- ²²Department of Neurology, Mie University School of Medicine, Mie, Japan
- ²³Department of Medical Welfare, Suzuka University of Medical Science Faculty of Health Science, Mie, Japan
- ²⁴National Centre Hospital, National Centre of Neurology and Psychiatry, Tokyo, Japan

Acknowledgements The authors thank the patients for participating in the study, Dr Mitsuru Kawai, National Hospital Organisation East Saitama National Hospital, for providing advice and Mr Brent Bell for reading the manuscript.

Contributors TT designed the study, conducted the mutational analysis, analysed the data, and drafted and revised the paper. MA supervised the study and revised the paper. NSu analysed the data, and drafted and revised the draft paper. MT analysed the data and revised the draft paper. CY, HSa, MH, HSu, MI, EA-K and NSH performed the mutational analysis and revised the draft paper. TI, SKur, TW, GS, NF, TS, TM, IF, EM, TK, MM, MYa, TH, JS, ST, SKuz and HT analysed the data and revised the draft paper. MYo, HK, HO and YI supervised the study and revised the draft paper.

Funding This work was supported by Intramural Research Grants (20B-12, 20B-13, 23-4 and 23-5) for Neurological and Psychiatric Disorders of NCNP.

Competing interests None.

Patient consent Obtained.

Ethics approval The study was approved by the National Hospital Organisation Nishitaga National Hospital and Tohoku University School of Medicine.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. **Liu J**, Aoki M, Illa I, *et al.* Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. *Nat Genet* 1998;**20**:31–6.
2. **Bashir R**, Britton S, Strachan T, *et al.* A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. *Nat Genet* 1998;**20**:37–42.
3. **Anderson LV**, Davison K, Moss JA, *et al.* Dysferlin is a plasma membrane protein and is expressed early in human development. *Hum Mol Genet* 1999;**8**:855–61.
4. **Matsuda C**, Aoki M, Hayashi YK, *et al.* Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. *Neurology* 1999;**53**:1119–22.
5. **Saito A**, Higuchi I, Nakagawa M, *et al.* Miyoshi myopathy patients with novel 5' splicing donor site mutations showed different dysferlin immunostaining at the sarcolemma. *Acta Neuropathol* 2002;**104**:615–20.
6. **Tagawa K**, Ogawa M, Kawabe K, *et al.* Protein and gene analyses of dysferlinopathy in a large group of Japanese muscular dystrophy patients. *J Neurol Sci* 2003;**211**:23–8.
7. **Piccolo F**, Moore SA, Ford GC, *et al.* Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. *Ann Neurol* 2000;**48**:902–12.
8. **Matsuda C**, Hayashi YK, Ogawa M, *et al.* The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. *Hum Mol Genet* 2001;**10**:1761–6.
9. **Tateyama M**, Aoki M, Nishino I, *et al.* Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy. *Neurology* 2002;**58**:323–5.
10. **Matsumura T**, Aoki M, Nagano A, *et al.* Molecular genetic analysis of dysferlin in Japanese patients with Miyoshi myopathy. *Proc Japan Acad* 1999;**75**, Ser. B:207–12.
11. **Saito H**, Suzuki N, Ishiguro H, *et al.* Distal anterior compartment myopathy with early ankle contractures. *Muscle Nerve* 2007;**36**:525–7.
12. **Illia I**, Serrano-Munuera C, Gallardo E, *et al.* Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. *Ann Neurol* 2001;**49**:130–4.
13. **Takahashi T**, Aoki M, Tateyama M, *et al.* Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. *Neurology* 2003;**60**:1799–804.
14. **Aoki M**, Liu J, Richard I, *et al.* Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. *Neurology* 2001;**57**:271–8.
15. **Argov Z**, Sadeh M, Mazor K, *et al.* Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. *Brain* 2000;**123**:1229–37.
16. **Mahjneh I**, Marconi G, Bushby K, *et al.* Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. *Neuromuscul Disord* 2001;**11**:20–6.
17. **Nguyen K**, Bassez G, Bernard R, *et al.* Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. *Hum Mutat* 2005;**26**:165.
18. **Cagliani R**, Magri F, Toscano A, *et al.* Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. *Hum Mutat* 2005;**26**:283.
19. **Nguyen K**, Bassez G, Krahn M, *et al.* Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. *Arch Neurol* 2007;**64**:1176–82.
20. **Leshinsky-Silver E**, Argov Z, Rozenboim L, *et al.* Dysferlinopathy in the Jews of the Caucasus: a frequent mutation in the dysferlin gene. *Neuromuscul Disord* 2007;**17**:950–4.
21. **Guglieri M**, Magri F, D'Angelo MG, *et al.* Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. *Hum Mutat* 2008;**29**:258–66.
22. **Krahn M**, Bérout C, Labelle V, *et al.* Analysis of the DYSF mutational spectrum in a large cohort of patients. *Hum Mutat* 2009;**30**:E345–75.
23. **Paradas C**, Llauger J, Diaz-Manera J, *et al.* Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. *Neurology* 2010;**75**:316–23.
24. **Klinge L**, Aboumoussa A, Eagle M, *et al.* New aspects on patients affected by dysferlin deficient muscular dystrophy. *J Neurol Neurosurg Psychiatry* 2010;**81**:946–53.
25. **Aoki M**, Lin CL, Rothstein JD, *et al.* Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. *Ann Neurol* 1998;**43**:645–53.
26. **Brooke MH**, Griggs RC, Mendell JR, *et al.* Clinical trial in Duchenne dystrophy. I. The design of the protocol. *Muscle Nerve* 1981;**4**:186–97.
27. **Nagashima T**, Chuma T, Mano Y, *et al.* Dysferlinopathy associated with rigid spine syndrome. *Neuropathology* 2004;**24**:341–6.
28. **Takahashi T**, Aoki M, Imai T, *et al.* A case of dysferlinopathy presenting choreic movements. *Mov Disord* 2006;**21**:1513–15.

29. **Klinge L**, Dean AF, Kress W, *et al*. Late onset in dysferlinopathy widens the clinical spectrum. *Neuromuscul Disord* 2008;**18**:288–90.
30. **Paradas C**, González-Quereda L, De Luna N, *et al*. A new phenotype of dysferlinopathy with congenital onset. *Neuromuscul Disord* 2009;**19**:21–5.
31. **Nishida Y**, Ishimoto S, Kobayashi T, *et al*. Two sisters with autosomal recessive muscular dystrophy (Miyoshi) with early involvement of limb girdle muscles (in Japanese). *Rinsho Shinkeigaku* 1987;**27**:756–9.
32. **Ueyama H**, Kumamoto T, Horinouchi H, *et al*. Clinical heterogeneity in dysferlinopathy. *Intern Med* 2002;**41**:532–6.
33. **Miyoshi K**, Kawai H, Iwasa M, *et al*. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. *Brain* 1986;**109**:31–54.
34. **Fisher D**, Walter MC, Kesper K, *et al*. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. *J Neurol* 2005;**252**:538–47.
35. **Kesper K**, Kornblum C, Reimann J, *et al*. Pattern of skeletal muscle involvement in primary dysferlinopathies: a whole-body 3.0-T magnetic resonance imaging study. *Acta Neurol Scand* 2009;**120**:111–18.
36. **Kuru S**, Yasuma F, Wakayama T, *et al*. A patient with limb girdle muscular dystrophy type 2B (LGMD2B) manifesting cardiomyopathy (in Japanese). *Rinsho Shinkeigaku* 2004;**44**:375–8.
37. **Wenzel K**, Geier C, Qadri F, *et al*. Dysfunction of dysferlin-deficient hearts. *J Mol Med* 2007;**85**:1203–14.
38. **Choi ER**, Park SJ, Choe YH, *et al*. Early detection of cardiac involvement in Miyoshi myopathy: 2D strain echocardiography and late gadolinium enhancement cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2010;**12**:31.
39. **Cagliani R**, Fortunato F, Giorda R, *et al*. Molecular analysis of LGMD-2B and MM patients: identification of novel DYSF mutations and possible founder effect in the Italian population. *Neuromuscul Disord* 2003;**13**:788–95.